Health insurance; require coverage for biomarker testing for certain purposes when supported by medical and scientific evidence.

SB 2694 requires all health insurance plans renewing or starting after July 1, 2026, to cover biomarker testing for disease diagnosis, treatment, or monitoring when supported by medical evidence. This directly affects insurers and policyholders by mandating coverage for genetic or molecular tests (like genomic sequencing) that align with FDA approvals, CMS guidelines, or nationally recognized clinical practice standards. Insurers must provide written justification for denied claims and update coverage policies publicly by September 1, 2026, with the Department of Insurance authorized to audit compliance. The law aims to reduce barriers to evidence-based testing without specifying new costs or outcomes.